These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 8453623

  • 1. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA, Durrani FA, Rustum YM.
    Cancer Res; 1993 Apr 01; 53(7):1560-4. PubMed ID: 8453623
    [Abstract] [Full Text] [Related]

  • 2. Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
    Van Laar JA, Mayhew EG, Cao S, Durrani FA, Peters GJ, Rustum YM.
    Eur J Cancer; 1995 Jun 01; 31A(6):974-6. PubMed ID: 7646931
    [Abstract] [Full Text] [Related]

  • 3. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cao S, Rustum YM, Spector T.
    Cancer Res; 1994 Mar 15; 54(6):1507-10. PubMed ID: 8137256
    [Abstract] [Full Text] [Related]

  • 4. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA.
    J Natl Cancer Inst; 1982 Feb 15; 68(2):227-31. PubMed ID: 6950156
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
    Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Casper ES, Young CW.
    Cancer Res; 1983 May 15; 43(5):2317-21. PubMed ID: 6187448
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
    van Laar JA, van der Wilt CL, Rustum YM, Noordhuis P, Smid K, Pinedo HM, Peters GJ.
    Clin Cancer Res; 1996 Aug 15; 2(8):1327-33. PubMed ID: 9816304
    [Abstract] [Full Text] [Related]

  • 7. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
    Cao S, Frank C, Rustum YM.
    J Natl Cancer Inst; 1996 Apr 03; 88(7):430-6. PubMed ID: 8618234
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES, Vale K, Williams LJ, Martin DS, Young CW.
    Cancer Res; 1983 May 03; 43(5):2324-9. PubMed ID: 6831457
    [Abstract] [Full Text] [Related]

  • 12. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Valdivieso M, Moore EC, Burgess AM, Marti JR, Russ J, Plunkett W, Loo TL, Bodey GP, Freireich EJ.
    Cancer Treat Rep; 1980 May 03; 64(2-3):285-92. PubMed ID: 7407763
    [No Abstract] [Full Text] [Related]

  • 13. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Kemeny N, Schneider A, Martin DS, Colofiore J, Sawyer RC, Derby S, Salvia B.
    Cancer Res; 1989 Aug 15; 49(16):4636-9. PubMed ID: 2472883
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC, Howell SB.
    Cancer Res; 1985 Aug 15; 45(8):3598-604. PubMed ID: 4016741
    [Abstract] [Full Text] [Related]

  • 16. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S, McGuire JJ, Rustum YM.
    Clin Cancer Res; 1999 Jul 15; 5(7):1925-34. PubMed ID: 10430100
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
    Moyer JD, Smith PA, Levy EJ, Handschumacher RE.
    Cancer Res; 1982 Nov 15; 42(11):4525-31. PubMed ID: 7127293
    [Abstract] [Full Text] [Related]

  • 19. A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine.
    Goz B, Bastow KF.
    Mutat Res; 1997 Aug 15; 384(2):89-106. PubMed ID: 9298118
    [Abstract] [Full Text] [Related]

  • 20. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Grem JL, Yee LK, Schuler B, Hamilton JM, Chen AP, Chabuk C, Grollman F, Grabenc M, Allegra CJ, Takimoto CH.
    Ann Oncol; 2001 Nov 15; 12(11):1581-7. PubMed ID: 11822758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.